25.3 Xanthines, Leukotriene Modifiers, and Mast Cell Stabilizers

Xanthines, Leukotriene Modifiers, and Mast Cell Stabilizers

Xanthines, leukotriene modifiers, and mast cell stabilizers each target a different piece of the respiratory disease puzzle. Xanthines directly relax airway smooth muscle, leukotriene modifiers block specific inflammatory pathways, and mast cell stabilizers prevent the release of inflammatory mediators before they can cause trouble. Together, they give clinicians several options for long-term control of asthma, COPD, and allergic airway conditions.

For nurses, knowing the mechanism, side-effect profile, and monitoring requirements of each class is essential for safe administration and effective patient teaching.

Xanthines, Leukotriene Modifiers, and Mast Cell Stabilizers Treating Respiratory Disorders

Xanthines (theophylline, aminophylline)

Xanthines are bronchodilators that work through two main mechanisms:

1. They inhibit phosphodiesterase (PDE) enzymes, which increases intracellular cyclic AMP (cAMP) levels. Higher cAMP causes airway smooth muscle to relax, opening the airways.
2. They antagonize adenosine receptors. Adenosine normally promotes bronchoconstriction and inflammation, so blocking it reduces both.

Beyond bronchodilation, xanthines also stimulate the medullary respiratory center in the brain, which improves respiratory drive. This is why theophylline's IV form, aminophylline, is sometimes used in neonatal apnea of prematurity (though caffeine citrate is more commonly preferred today). Xanthines also have mild anti-inflammatory effects in the airways.

Leukotriene Modifiers (montelukast, zafirlukast, zileuton)

Leukotrienes are potent inflammatory mediators released during the allergic response. They cause bronchoconstriction, increased mucus production, and airway edema. Leukotriene modifiers interrupt this process through two different approaches:

• Leukotriene receptor antagonists (LTRAs) like montelukast and zafirlukast compete with leukotrienes at the CysLT1 receptor, blocking their effects on the airways.
• 5-lipoxygenase inhibitors like zileuton work upstream by preventing leukotriene synthesis altogether. They block the enzyme (5-lipoxygenase) that produces leukotrienes from arachidonic acid.

Both subtypes reduce airway inflammation, bronchoconstriction, and mucus secretion. These drugs are oral medications used for long-term control, not acute rescue.

Mast Cell Stabilizers (cromolyn sodium, nedocromil)

Mast cell stabilizers work prophylactically by stabilizing the mast cell membrane, preventing degranulation. When mast cells degranulate, they release histamine, leukotrienes, and other inflammatory mediators that trigger bronchoconstriction and airway inflammation. By keeping the mast cell intact, these drugs prevent the allergic cascade from starting.

The key point: mast cell stabilizers are preventive only. They have no role in treating an acute asthma attack. They must be used regularly over days to weeks before full benefit is seen.

Indications, Side Effects, and Drug Interactions

Indications

Side Effects

Xanthines have the most concerning side-effect profile because of their narrow therapeutic index (therapeutic serum level: 5–15 mcg/mL). At therapeutic levels you may see nausea, vomiting, headache, and insomnia. As levels rise toward toxicity, more serious effects appear: tachycardia, arrhythmias, and seizures. Toxicity can be life-threatening.

Leukotriene modifiers are generally well tolerated. Common effects include headache, nausea, diarrhea, and abdominal pain. Zileuton specifically requires monitoring of liver function tests (LFTs) because it can cause hepatotoxicity. The FDA has also added a boxed warning to montelukast for neuropsychiatric events (mood changes, agitation, suicidal thinking), so patients and caregivers should be educated to watch for behavioral changes.

Mast cell stabilizers have a mild side-effect profile. Inhaled forms may cause throat irritation, cough, and an unpleasant taste. Oral forms can cause headache and nausea. Serious adverse effects are rare.

Drug Interactions

• Xanthines are metabolized by CYP450 enzymes (primarily CYP1A2). Drugs that inhibit these enzymes raise theophylline levels and increase toxicity risk. Watch for interactions with cimetidine, erythromycin, ciprofloxacin, and fluvoxamine. Conversely, CYP1A2 inducers like phenytoin, rifampin, and cigarette smoking lower theophylline levels, potentially making it less effective.
• Leukotriene modifiers: Zafirlukast and zileuton can inhibit CYP enzymes and may increase levels of warfarin (raising bleeding risk). Zileuton can also increase theophylline levels if used together. Monitor INR closely when combining zafirlukast or zileuton with warfarin.
• Mast cell stabilizers have few clinically significant drug interactions, which is one of their advantages.

Essential Nursing Considerations

Before administration:

• Assess respiratory status: lung sounds, oxygen saturation ($SpO_2$), respiratory rate, and peak expiratory flow rate (PEFR) if applicable.
• Review current medications for potential drug interactions, especially with xanthines.
• Check baseline labs as indicated: theophylline serum levels for xanthine therapy, LFTs for zileuton.

During therapy:

• Monitor theophylline serum levels regularly. The therapeutic range is 5–15 mcg/mL. Signs of toxicity (nausea, restlessness, tachycardia, arrhythmias, seizures) can develop quickly if levels exceed this range.
• Monitor LFTs periodically for patients on zileuton (before treatment, then periodically during therapy).
• Watch for neuropsychiatric symptoms in patients taking montelukast, including mood changes, sleep disturbances, and agitation.
• Reassess respiratory status regularly to evaluate treatment effectiveness.

General considerations:

• Mast cell stabilizers and leukotriene modifiers are maintenance medications, not rescue drugs. Ensure patients have access to a short-acting beta-2 agonist (SABA) like albuterol for acute symptoms.
• Teach proper inhaler or nebulizer technique for inhaled medications. Have the patient demonstrate the technique back to you.
• Remind patients that mast cell stabilizers require consistent, regular use before they become effective.

Patient Education

• Purpose of the medication: Explain that these are controller/maintenance medications taken on a schedule, not as-needed rescue inhalers. Patients need to understand the difference.
• Administration technique: For inhaled mast cell stabilizers, demonstrate proper inhaler or nebulizer use and have the patient return-demonstrate. For oral medications (montelukast, zafirlukast, zileuton, theophylline), review timing with meals if relevant. Zafirlukast, for example, should be taken 1 hour before or 2 hours after meals because food decreases absorption.
• Adherence: Emphasize that skipping doses reduces effectiveness, especially for mast cell stabilizers and leukotriene modifiers where consistent use is needed for benefit.
• Side effects to report: Teach patients to contact their provider for signs of theophylline toxicity (persistent nausea, rapid heartbeat, tremors, confusion), behavioral or mood changes on montelukast, or signs of liver problems on zileuton (jaundice, dark urine, unusual fatigue, right upper quadrant pain).
• Trigger avoidance: Advise patients to identify and minimize exposure to known allergens and irritants (smoke, dust, pet dander) alongside medication use.
• Rescue medication use: Make sure patients know when and how to use their SABA inhaler and understand that needing it frequently (more than 2 days per week) may indicate their controller therapy needs adjustment.
• Follow-up: Stress the importance of regular appointments to monitor drug levels, labs, and overall treatment response.